Referenser för ADHD

Författare, artikel och publikation

År

Hämta abstract / fulltext

1. Colquhoun I, Bunday S. A lack of essential fatty acids as a possible cause of hyperactivity in children.

Medical Hypothesis 1981; 7: 673-9.

1981

2. Baker SM. A biochemical approach to the problem of dyslexia.

J Learn Disabil 1985; 18: 581-4.

3. Stevens LJ, Zentall SS, Deck JL, et al. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder.
Am J Clin Nutr 1995; 62: 761-8.

4. Burgess JR. Attention deficit hyperactivity disorder; observational and interventional studies.

NIH workshop on omega-3 essential fatty acids in psychiatric disorder;

National Institutes of Health, Bethesda, USA, 1998; Sept 2-3. 

5. Hibbeln JR. Fish consumption and major depression.

Lancet 1998; 351: 12-3.

6. Voigt RG, Uorente AM, Berretta MC, Boutte C, Fraley JK, Jensen CL, Heird WC.

Docosahexaenoic acid (DHA) supplementation does not improve the symptoms of attention-deficit
hyperactivity disorder (ADHD).

Pediatr Res 1999; 45: 17A.

7.Bennet CN, Horrobin DF. Gene targets related to phospholipids and fatty acid metabolism in schizophrenia and other psychiatric disorders: an update.

Prostaglandins Leukotr Essent Fatty Acids 2000; 63: 47-59.

9. Hibbeln JR. Seafood consumption, the DHA content of mothers milk and prevalence of post-partum depression; a cross-national ecological analysis.

J Affect Dis 2001. 

10. Hurt-Canejo E, Canejo G, Peilot H, Oomi K, Kovanen P.
Phospholipase A(2) in vascular disease.

Circ Res 2001; 89: 298-304.

11. Pawlosky RJ et al. Physiological compartmental analysis of alpha-linolenic acid metabolism in adult humans.

Journ. of Lipid Research. 2001.42,1257-65.

12. Peet M, Brind J, Ramchand CN, Shah S, Vankar GK. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia.

Schizophr Res 2001; 49: 243-51.

13. Puri BK, Counsell SJ, Hamilton G, Richardson AJ, Horrobin DF. Eicosapentaenoic acid (EPA) in treatment-resistant depression associated with symptom remission, structural brain changes and reduced neuronal phospholipid turnover.

Int J Clin Prac 2001; 55: 560-3.

14. Richardson AJ. Fatty acids in dyslexia, dyspraxia, ADHD and the autistic spectrum.

The Nutrition Practitioner, October 2001.

15. Tanskanen A, Hibbeln JR, Hintikka J, Haatainen K, Honkalampi K, Vinamaki H. Fish consumption, depression and suicidality in a general population.

Arch Gen Psychiatry 2001; 58: 512-3.

17. Lonergan PE, Martin DS, Horrobin DF, Lynch MA. Neuroprotective effect of eicosapentaenoic acid in hippocampus of rats exposed to gamma irradiation.

J Biol Chem 2002; 277(23): 20804-11.

18. Mortensen EL, Michaelsen KF, Sanders SA, Reinisch JM. The association between duration of brestfeeding and adult intelligence.

JAMA 2002; 287: 2365-71.

19. Oatridge A, Holdcroft A, Saeed N, Hajnal JV, Puri BK, Fusi L, Bydder GM. Change in brain size during and after pregnancy: study in healthy women and women with preeclampsia.

Am J Neuroradiol 2002; 23: 19-26.

20. Peet M, Horrobin DF. A dose ranging study of the effects of ethyl eicosapentaeonate in patients with ongoing depression in spite of apparently adequate treatment with standard drugs.
Arch Gen Psychiatry 2002; 59: 913-9.​

​

21. Portwood, M. Developmental dyspraxia: the significance of diet.
Special Magazine, March 2002.
​

22. Puri BK, Counsell SJ, Zaman R, Main J, Collins AG, Hajnal JV, Davey NJ. Relative increase in choline in the occipital cortex in chronic fatigue syndrome.
Acta Psychiatria Scand 2002; 106: 224-6.
​

23. Richardson AJ, Puri BK. A randomised, double blind placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties.

Prog Neuropsychopharm Biol Psychiat 2002; 26: 233-9.

25. Vaddadi KS, Soosai E, Chiu E, Dingian P. A randomised placebo-controlled, double-blind study of treatment of Huntington’s disease with unsaturated fatty acids.

Neuroreport 2002; 13: 29-33.

28 Puri BK. Eicosapentaenoic Acid (EPA) rich essential Fatty Acid supplementation in Chronic Fatigue Syndrome associated with symptom remission and structural brain changes.

Int. Clin.Practice. 2004 mars;58(3):297-9.

29. Richardson AJ. The Oxford-Durham Study: A randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder.

Pediatrics.2005; 115(5):1360-1366.

30. Portwood MM. The role of dietary fatty acids in children's behaviour and learning.

Nutrition and Health. 2006; 18:  233 - 247.

31. Sinn N, Bryan J. Effect of supplementation with polyunsaturated fatty acids and micronurients on learning and behavior problems associated with child ADHD.

J Developmental & Behavioral Pediatrics 2007; 28: 82 - 91.

32. Gustafsson PA, Birberg-Thornberg U, Duchén K, Strandvik B, Karlsson T. "HPEPA-01" - Placebo-controlled, randomised, double-blind, multicenter study of PLUSEPA as treatment for ADHD with co-morbidity in Swedish Children ages 7-12.

Presented at ISSFAL 2008 in Kansas City, MO, May 17-22, 2008.

33. Jazayeri S, Tehrani-Doost M, Keshavarz SA, et al. Plus-EPA secures its position as antidepressant: "Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acis and fluoxetine, separately and in combination, in a major depresive disorder."

Australian and New Zealand Journal of Psychiatry 2008; Mar 42(3): 192 - 8.

34. Johnson M, Östlund S, Fransson G, Kadesjö B, Gillberg Ch. Omega-3/Omega-6 fatty acids for attention deficit hyperactivity disorder. A randomized placebo-controlled trial in children and adolescents.

J of Att Dis 2008; XX: xx - xx.